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1. Introduction 
Glucocorticoids (GC) are commonly used as anti-inflammatory and immunosuppressive 
therapy by approximately 1% of the total adult population. Glucocorticoid therapy has also 
been used in non-autoimmune and non-inflammatory conditions such as acute myocardial 
infarction, angina, endocarditis as well as in invasive cardiology, coronary interventions and 
cardiopulmonary- bypass surgery. Despite ample evidence for GC’s role as a natural, 
physiologic regulator of the immune system, little is known about the molecular events 
induced by GCs during a stress response.  Autophagy is a survival mechanism which is 
upregulated in response to stress in the cell. It has been described as the cell’s major 
adaptive strategy in response to a multitude of extracellular stresses, such as nutrient 
deprivation, mitochondrial damage, endoplasmic reticulum stress or infection. Conserved in 
all eukaryotes, it is mediated by a unique organelle, the autophagosome, which, under 
inclusion of cytoplasmic cargo, fuses with lysosomes in order to yield recyclable nutrient 
metabolites. Basal autophagic activity plays a vital role in maintaining homeostasis during 
cellular stress. Its malfunction has been implicated with human pathologies such as heart 
disease, neurological storage disease and cancer.  
It is known that GC-triggered autophagy plays a role in cell death during development. 
However, recent landmark studies also indicate that autophagy operates as a hub, 
integrating cellular stress, metabolism and glucocorticoid mediated anti-inflammatory 
action. Importantly, recent lines of evidence suggest that glucocorticoids impact on key 
signalling components, which control the activity of the autophagic machinery.    
In this review we will focus on the connections between these key signaling components 
and autophagy, describing their central roles as modulators of GC-induced protection 
during a cellular stress response.  
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2. Glucocorticoid generation and metabolism 
The understanding of the physiological regulation of glucocorticoid activity has 
considerably improved over the last few decades. The generation of glucocorticoids from 
cholesterol, which occurs in the zonae fasiculata and reticularis of the adrenal cortex, is 
tightly regulated by the hypothalamic-pituitary-adrenal (HPA) axis where glucocorticoids 
regulate its own generation through negative feedback inhibition.  Glucocorticoids are 
produced de novo under this control and are released into the blood as required, with a 
definite circadian rhythm producing peak concentrations in the early morning [1]. When 
secreted into the blood, most (90-95%) of glucocorticoids are sequestered to corticosteroid-
binding globulin and albumin with the unbound fraction available to interact with their 
receptors [2]. Metabolic inactivation of glucocorticoids occurs predominantly in the liver, 
but also in the kidney with inactive metabolites excreted in the urine.  
3. Molecular actions of glucocorticoids: Genomic and non-genomic 
pathways 
The classical mode of glucocorticoid-induced gene expression, i.e. the genomic effect 
involves ligand-dependent activation and release from chaperone proteins (heat shock 
protein-90 and others), translocation of the receptor-complex to the nucleus where binding 
of the glucocorticoid receptor to glucocorticoid response element (GRE) in the promoter of 
the target genes will lead to transcriptional activation of the genes within hours [3, 4]. 
Activation of glucocorticoid-responsive genes occurs via interaction between the DNA-
bound GR and transcriptional co-activator molecules such as CREB-binding protein, which 
have intrinsic histone acetyltransferase activity and cause acetylation of core histones. This 
tags histones to recruit chromatin remodeling engines and subsequent association of RNA 
polymerase II resulting in gene activation [5]. Increasing evidence suggests that 
glucocorticoids can also cause rapid activation of signaling molecules prior to altering gene 
expression. These so called non-genomic effects occur within minutes of glucocorticoid 
exposure and are not affected by inhibiting RNA transcription [5, 6].  
Metabolic effects of glucocorticoids represent most of the adverse effects of glucocorticoid 
therapy and are mainly ascribed to the transcriptional activity of the glucocorticoid receptor, 
whereas the therapeutically beneficial anti-inflammatory actions are thought to be 
predominantly caused by the mechanism of transrepression where the activated GR can 
selectively repress the transcription of specific inflammatory genes without binding to DNA 
itself but by a number of pleiotropic actions at the promoters of inflammatory genes. 
Inflammatory genes are regulated by the actions of proinflammatory transcription factors 
such as nuclear factor-B (NF-B), activator protein -1 (AP-1), and signal transducer and 
transcription proteins. Activated GR binds to these transcription factors, either directly or 
indirectly, and recruits co-repressor proteins that blunt the ability of these transcription 
factors to switch on inflammatory genes [7]. Furthermore, many pro-inflammatory genes are 
repressed by GC at post-transcriptional level via mRNA destabilization or inhibition of 
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translation, however, this phenomenon cannot be accounted for by transrepression, 
therefore suggest the existence of an additional anti-inflammatory mechanism of GCs [8].  
4. Ischemia/reperfusion-induced stress in the heart 
Glucocorticoids play a key role in the response to stress in the heart where it can influence 
the regulation of blood pressure, inflammation, immune function and cellular energy 
metabolism [9-10]. These acute effects contribute to an adaptive response in the short term. 
Although the cardioprotective effects of glucocorticoids in the acute setting of 
ischemia/reperfusion have been experimentally demonstrated in animals [11-13] and 
humans [14], the molecular mechanisms still need to be fully elucidated.  
Ischemia can be defined as an imbalance between the amount of oxygen, glucose and other 
substrates needed by the heart [15,16]. This leads to anaerobic metabolism and reduced 
contractile function. A biochemical imbalance occurs as the maintenance of the metabolism 
cannot be kept at a steady state due to inadequate coronary flow. A reduction in metabolite 
clearance also occurs during ischemia and intracellular pH levels drop as the acid by-
products of glycolysis accumulate. The severity of ischemic injury depends on the duration 
of ischemia and subsequent reperfusion [15,16]. If, ischemia is maintained, reversible injury 
gradually transitions to irreversible injury and a myocardial infarct develops. Reperfusion 
with its reinforced oxygen and substrate availability is thus a prerequisite for myocardial 
salvage [16]. However, reperfusion after an ischemic period causes generation of free 
radicals and is associated with detrimental changes such as enzyme release, arrhythmias and 
intramyocardial haemorrhage which are known as reperfusion injuries [17]. Cardiomyocytes 
are highly dependent on a continuous supply of oxygen. During ischemia, cardiomyocyte 
capacity to generate sufficient ATP and creatine phosphate becomes depleted and multiple 
adaptive processes occur in response to these hypoxic environments created during ischemia. 
To reduce oxygen consumption, oxidative phosphorylation is limited and glycolysis is 
stimulated. This aids in ATP production, even under low oxygen supply [18]. Prolonged 
ischemia leads to cardiac failure which is characterized by the progressive death of myocytes 
[19]. Three major morphologies of cell death have been described, viz. apoptosis (type I), cell 
death associated with autophagy (type II) and necrosis (type III).  
5. The basic mechanisms of Autophagy 
Autophagy, from greek self eating, is a conserved degradation and recycling system for long-
lived proteins and other sub-cellular constituents. This degradation system is inherent to all 
eukaryotes and is mediated by a unique organelle, the autophagosome, which, under 
inclusion of cytoplasmic cargo, fuses with lysosomes in order to yield recyclable nutrient 
metabolites. Although already described in 1966 by de Duve and Wattiaux [20], Autophagy 
has received significant renewed attention in the last years. This new interest is primarily 
based on the recently gained understanding of the molecular components of the autophagic 
machinery. Genetic analyses in yeast identified more than 30 autophagy-related genes 
(ATG), and their corresponding proteins (Atg) participating in the autophagic pathway [21].  
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Multiple mechanisms exist for the mode of delivery of cytoplasmic material to the lysosome, 
giving rise to different types of autophagy. While microphagy is characterized by cytoplasm 
engulfment directly at the lysosomal surface by invagination of its membrane, 
macroautophagy involves the synthesis of double-membrane vesicles, which sequester 
portions of the cytoplasm [22]. Chaperone mediated autophagy (CMA) on the other hand 
involves selective motif tagged protein translocation directly through the lysosomal 
membrane [23]. However, shared by all three mechanisms is the final step of lysosomal 
cargo degradation by hydrolases, allowing the recycling of degraded material. Here we will 
focus on macroautophagy (herein referred to as autophagy), as it is the primary mechanism 
for cytoplasm-to-lysosome delivery.  
The autophagic process can be divided into distinct steps, which include the induction, 
cargo packaging, vesicle nucleation, vesicle expansion and protein retrieval, docking and 
fusion and finally vesicle degradation [21]. In brief, the first event is the formation of the 
isolation membrane of the autophagosome. The Atg1 kinase complex governs these early 
steps in autophagosome formation. Central to this regulation is the nutrient sensor kinase 
mTOR (TORC). When mTOR is suppressed due to nutrient starvation, Atg1 kinase activity 
is triggered and affinity for Atg13 increases [24], which leads to the recruiting of other Atg 
proteins to initiate autophagosome formation. Cellular sources for this autophagosome 
formation step have been shown to be Golgi, ER, mitochondria and the plasma membrane 
[25]. During this process, two strongly interdependent conjugation systems are coordinating 
the events leading to the formation, elongation and sealing of the isolation membrane [26]. 
In the first conjugation system, Atg proteins 5, 7, 10 and 12 undergo a multimerization step 
with Atg16, leading to the formation of an Atg16 homotetramer, which assembles with four 
Atg12-Atg5 conjugates [27]. In the second conjugation system, the protein Atg8 is Atg4 
dependently conjugated with phosphatidylethanolamine (PE) [28]. Reactive oxygen species 
play a role in controlling this step, as Atg4 oxidization enables autophagosome formation to 
proceed [29]. Next, two kinase complexes, PI3 kinase and Atg1, participate in the late stages 
of autophagosome formation. Atg6 (the mammalian orthologue, beclin-1) belongs to the PI3 
kinase (PI3-K) class III complex. When Atg1 interacts with Atg13, progression towards a 
complete autophagosome takes place [27]. Cytoplasmic cargo is now confined. Docking and 
fusion with a lysosome will allow acidification of the autophagosome lumen, leading to the 
complete and rapid degradation of cargo into constituent components that are released into 
cytoplasmic space via permeases (Figure 1). 
6. Autophagy as a protective response during stress in the heart 
The terminally differentiated nature of cardiomyocytes demands a strong molecular reliance 
upon a functional autophagic degradation system. In cardiomyocytes autophagy has been 
described already in the late 1970’s where it was emphasized as an important repair 
mechanism of sublethal injury [30]. Sybers and coworkers demonstrated the occurrence of 
myocyte autophagy in a fetal mouse heart that was kept for 1 h in organ culture. In addition 
they observed that Autophagy was accelerated by oxygen and glucose deprivation, but the 
hearts function could be restored following resupply of glucose and oxygen. However, 
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when the period of injury lasted for longer than four hours, necrotic cell death was induced 
[30]. To date, many models have produced clear evidence that upregulation of autophagy 
promotes cell survival under conditions of metabolic perturbations and energy deprivation 
[31-33]. In the ischaemic myocardium, autophagy is upregulated rapidly following 20 
minutes of coronary artery occlusion, leading to an increased number in autophagosomes 
[34]. In isolated cardiomyocytes exposed to anoxia-reoxygenation it was shown that 
inhibition of autophagy leads to an increase in necrotic cell death, which was further 
increased by additional inhibition of apoptosis [35]. However, enhancing autophagic flux, as 
indicated by an increased rate of autophagosomal clearance, protects cardiac myocytes 
against ischaemic injury by reducing apoptosis [31]. Moreover, the homeostatic role of 
functional basal autophagic activity in the myocardium has been demonstrated by cardiac 
specific disruption of Atg5, manifesting in impaired contractility, hypertrophy, dilation and 
sarcomeric disarray [36-37].  
 
 
 
 
Figure 1. Schematic representation of the autophagic process, indicating the signalling network from 
induction to permease efflux with amino acid release, providing substrates for the TCA cycle. 
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7. Detrimental effects of Autophagy in the heart  
Literature suggests that autophagy is uniquely controlled during ischemia and reperfusion. 
A large body of evidence indicates that upregulation of autophagy particularly during the 
reperfusion phase is detrimental and exacerbates myocyte death. Energy sensing mediated 
by the 5’-AMP-activated protein kinase (AMPK) appears to be central to this control 
mechanism. In glucose-deprived cardiac myocytes, autophagy resulting from ischemia has 
been shown to be accompanied by AMPK activation, and was inhibited by dominant 
negative AMPK, suggesting an AMPK dependent mechanism [34]. AMPK is rapidly 
activated during myocardial ischemia, and leads to an increase in glucose uptake and 
oxidation as well as fatty acid oxidation [38]. Autophagy is enhanced after reperfusion, 
which is accompanied by an inactivation of AMPK and an increase in beclin-1 [34]. As 
AMPK switches off ATP-dependent processes, [39] its inactivation at reperfusion may 
contribute to an unfavorable metabolic environment. Moreover, data indicate that energy 
sensing mediated by AMPK is also differentially controlled depending on the severity of 
the ischaemic insult [40]. These reports are strengthened by recent data derived from 
cultured myoblasts, where a differential induction of cell death was observed, which was 
dependent on the severity and duration of the ischaemic insult [33]. Only mild ischaemic 
injury induced autophagy and apoptosis, while severe injury led to primarily necrotic cell 
death.  
8. Autophagy and myocardial metabolism 
The total cellular ATP amount in the cardiac myocyte is consumed in less than one minute 
[41] indicating the very high metabolic demand of the myocardium, and at the same time 
highlighting the existence of an extremely efficient system of energy conversion. In 
ischaemic conditions, energy metabolism is disrupted to a level where energy production 
cannot meet the myocardial energy demand. However, there is a clear role for autophagy in 
ischemia to influence the cell’s energy profile, indicative to maintain metabolic supply-
demand homeostasis [33]. ATP levels decrease rapidly with ischemia and recover rapidly 
after reperfusion [42]. These dynamics of ATP depletion become highly relevant when 
considering the molecular overlap between autophagy, apoptosis and necrosis [32; 43-44, 
Figure 2]. It has been demonstrated that an ATP depletion of >50% is needed in order to 
change the mode of cell death from apoptotic to necrotic [45]. Vice versa, a progressive 
replacement of necrosis with apoptosis has been described, when intracellular ATP becomes 
available again [46]. Recent evidence strongly indicates the previously underestimated 
metabolic role of autophagy in generating metabolite substrates by shifting the cellular 
energetic balance [33; 47-49], suggesting that intracellular ATP availability may be 
controlled to a significant degree by the autophagic flux (Figure 2). These data strongly 
suggest that not only the magnitude of autophagic activity but also the cell’s metabolic 
profile and microenvironment are crucial in controlling a favorable cellular response other 
than necrosis, and delaying apoptosis [32] (Figure 3). 
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Figure 2. Recent evidence strongly indicates the previously underestimated metabolic role of 
autophagy in generating metabolite substrates and ATP by shifting the cellular energetic balance, with a 
direct and indirect effect on apoptosis and necrosis.  
 
Figure 3. Whether autophagy may manifest in cytoprotection or type II programmed cell death is 
dependent on the severity and duration of the ischaemic insult, as well as autophagic flux- and 
metabolic parameters.  
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The above results also stress the significance of the severity and duration of the ischaemic 
event, to allow a sufficient induction of the autophagic machinery to take place. In fact, a 
direct relationship between autophagic flux and myocardial function has recently been 
proposed [50], indicating the strong need to measure autophagic activity accurately.  
Further characterization of the autophagic flux in clear context with myocardial injury will 
help to answer questions when autophagy functions as a primarily destructive pathway, 
manifesting in type II programmed cell death or when autophagy functions in a 
cytoprotective manner.  
9. Autophagy and glucocorticoids-relationship and metabolic response  
The multifaceted relationship between autophagy and glucocorticoids is already indicated 
in embryogenesis. Recent reports not only demonstrate an important metabolic role for 
autophagy during embryogenesis and postnatal development [51,52], but also indicate a 
likely molecular link between autophagic programmed cell death and steroids during 
development [53]. Embryos from the atg5-/- knockout mouse model die perinatally due to 
energy depletion, leading to a reduced plasma- and tissue amino acid concentration [54]. 
Moreover, increased apoptosis is displayed in various embryonic tissues derived from such 
embryos, supporting a role for autophagy in the removal of apoptotic bodies or in delaying 
the onset of apoptotic cell death [54]. Targeted disruption of beclin 1 in mice also leads to 
early death in embryogenesis [55]. Many examples of autophagy as a mode of programmed 
cell death during embryogenesis exist, suggesting that an important role for autophagic cell 
death in development. It has been shown that autophagic cell death requires the genes 
ATG7 as well as beclin 1 and can be induced by caspase-8 inhibition [56]. In addition, 
embryonic fibroblasts from Bax/Bak double knockout mice undergo autophagic cell death, 
which can be suppressed by inhibitors of autophagy and which is dependent on ATG5. 
These data suggest a role for Bcl-2 family proteins controlling also non-apoptotic cell death 
in addition to regulating apoptosis [57]. Especially in lower eukaryotes, the rise in steroid 
titers can elicit a transcription regulatory hierarchy that results in synchronous autophagic 
cell death [53]. Such steroid triggered programmed autophagic cell death has been 
observed in larval salivary gland cells [53] as well as motorneurons [58]. These findings 
suggest that steroids can play a governing role in very specific scenarios, controlling 
autophagic activity and the duration of increased flux, which in turn can control the 
synchronous induction of cell death. It is however not known, whether a robust increase 
in cortisol release in humans following psychological stress, trauma, sepsis or starvation 
can elicit similar effects on autophagic activity during embryogenesis. Such studies 
deserve a great deal of attention.  
Although limited data are available, similarities exist between the role of the autophagic 
pathway as a response mechanism to metabolic perturbations and glucocorticoids in the 
regulation of metabolic responses.  Chronic excessive activation of glucocorticoid receptors 
leads to major cellular metabolic rearrangements such as insulin resistance, glucose 
intolerance and dyslipidaemia. Obesity and metabolic syndrome, which are characterized 
by a nutrient overload, have been associated with a hyperactivation of tissue mTOR, 
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indicating a blunted autophagic response [59]. The systemic glucocorticoid excess is 
associated with an increase in cardiovascular risk factors [60]. One of the major causes of 
impact on these risk factors is thought to be the glucocorticoid mediated intravascular 
volume overload [60]. As the access of glucocorticoids to their receptors is controlled by the 
isozymes of 11-β-hydroxysteroid dehydrogenase in a tissue specific manner, makes 
manipulation of this pathway an attractive therapeutic target. By selective isozyme 
inhibitors, the glucocorticoid activity can be modulated locally, keeping systemic 
glucocorticoid concentrations within homeostatic range.  
Also in the acute setting a relationship exists between glucocorticoid availability and 
autophagy induction. In the treatment of acute lymphoblastic leukemia, glucocorticoids are 
used as crucial therapeutic agent, due to their effect on inducing G1 phase cell cycle arrest 
and apoptosis. Recently it was shown that dexamethasone treatment induces cell death and 
involves the induction of autophagy before the onset of apoptosis [61]. Moreover, another 
level of interaction has been demonstrated as the role of autophagy in innate immunity has 
recently become clear. Both the ATG16L1 risk allele as well as ATG5 are selectively 
important for the function of the Paneth cell, a specialized epithelial cell in the small 
intestine [62]. Through genome-wide association screenings it was shown that the 
autophagic pathway plays a fundamental role in the predisposition to the inflammatory 
bowel condition Chron’s disease [63]. Taken together, these data indicate the dynamic 
relationship between glucocorticoid-induced metabolic perturbations, autophagy induction, 
inflammation and cell death susceptibility. Further investigations are likely to provide new 
insights into this complex relationship to treat cardiovascular disease more effectively by 
exploiting the modulation of the autophagic machinery in context with controlling local 
glucocorticoid activity.   
10. The role of the mitogen-activated protein kinases (MAPKs) during 
ischemia/reperfusion-induced stress in the heart 
Great efforts have been made to disentangle the intricate relationship between signalling 
pathways and the stress response of the heart during ischemia/reperfusion-induced injury. 
Analysis is complicated due to the fact that several pathways can be activated 
simultaneously with differential effects. It has become however evident that the MAPKs are 
major mediators of I/R-induced injury. Recent data pin point the MAPK’s as one of the 
crossroads between autophagy and glucocorticoid signalling events.  
Three major classes of MAPKs (Figure 4), which include the extracellular signal regulated 
protein kinase (ERK)/p42/44, c-Jun NH2-terminal protein kinase (JNK)/stress activated 
protein kinase (SAPK) and p38 MAPK families have been identified [64,65]. The ERK 
pathway has been depicted as a pro-survival pathway and is activated by a variety of 
mitogens and phorbol esters [66,67]. The JNK and p38 MAPK pathways are regarded as pro-
apoptotic pathways and are mainly activated by environmental stress and inflammatory 
cytokines [67,68].  
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Figure 4. MAPK activation in stress-induced signalling in the heart. A variety of stress signals can 
activate the MAPKs directly or indirectly. MAPKs comprise a family of tyrosine/threonine kinases. 
Receptor activation initiates a cascade of phosphorylation events involving sequential activation of G 
proteins, MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and finally MAPK. Activated 
MAPK, in turn, is responsible for the phosphorylation and activation of various other regulatory 
proteins and transcription factors, which induce the expression of genes involved in the regulation of 
cell proliferation and apoptosis. ERK kinases mediate cell survival and proliferation, whereas JNK and 
p38 induce growth arrest and apoptosis (modified from Wernig and Xu, 2002).  
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Studies using chemical inhibitors have led to the conclusion that activation of the p38-
MAPK promotes cardiac myocyte death during extended periods of ischemia [69-71].  In a 
cultured neonatal rat cardiac myocyte model, inhibition of p38-MAPK protects against 
ischaemic injury by decreasing LDH release [69,70]. In addition, Barancik and co-workers 
(2000) reported that a specific inhibitor of p38-MAPK, SB203580, protected pig myocardium 
against ischaemic injury in an in vivo model by reducing infarct size [71]. Several studies 
indicated that p38-MAPK plays a pivotal role in promoting myocardial apoptosis [69,72-73]. 
Ma and co-workers (1999) demonstrated that in isolated perfused rabbit hearts, ischemia 
alone caused a moderate but transient increase in p38-MAPK activity [72]. Ten minutes’ 
reperfusion further activated p38-MAPK, which remained elevated throughout reperfusion 
(20 minutes). Administration of SB203580 before ischemia and during reperfusion 
completely inhibited p38 MAPK activation and exerted significant cardioprotective effects, 
characterized by decreased myocardial apoptosis and improved post-ischaemic function, as 
well as attenuated myocardial necrotic injury. In contrast, administering SB203580 10 
minutes after reperfusion (a time point when maximal MAPK activation had already been 
achieved), failed to convey significant cardioprotection. Mackay and Mochly-Rosen (1999) 
indicated that in neonatal rat cardiac myocytes, two distinct phases of p38 activation were 
observed during ischemia: the first phase began within 10 minutes and lasted less than 1 
hour, and the second began after 2 hours and lasted throughout the ischaemic period [69]. 
They demonstrated that SB203580 also protected cardiac myocytes against ischemia by 
reducing activation of caspase-3, a key event in apoptosis. However, the protective effect 
was seen even when the inhibitor was present during only the second, sustained phase of 
p38 MAPK activation. Subsequent studies by Yue and co-workers (2000), exposing rat 
neonatal cardiomyocytes to ischemia showed a rapid and transient activation of p38-MAPK 
and JNK [73]. On reoxygenation, further activation of SAPKs was noted. With pretreatment 
of the cells with SB203580 apoptotic cells were reduced, suggesting p38 MAPK activation 
mediates apoptosis in rat cardiac myocytes subjected to ischemia/reoxygenation. In 
addition, Yue and co-workers (2000) also showed that SB203580 improved cardiac 
contractile function in rat isolated ischaemic hearts. Inhibition of p38 MAPK activation, 
therefore, correlated with cardioprotection against ischemia/reperfusion injury in cardiac 
myocytes as well as in isolated hearts [73]. 
Zechner and co-workers (1998) also reported that overexpression of MKK6 (Figure 4), an 
upstream activator of p38 MAPK, resulted in protection of cardiac myocytes from apoptosis 
induced either by anisomycin or MEKK1, an upstream activator of the JNK pathway [74]. In 
addition, expression of MKK6 elicited a hyperthrophic response, which was enhanced by 
co-infection of p38 [75]. Therefore, a distinct isoform of p38 MAPK, p38, may participate 
in mediating cell survival. In contrast, over expression of MKK3 in mouse cardiomyocytes 
led to apoptosis, which was increased by co-infection of p38 [75]. Therefore differential 
activation of p38-MAPK isoforms may exert opposing effects: p38 is implicated in cell 
death, while p38 may mediate myocardial survival. 
To determine whether p38 MAPK activation was isoform selective, rat neonatal 
cardiomyocytes were infected with adenovirus encoding wild-type p38 or p38 [70]. They 
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showed that transfected p38 and p38 were differentially activated during sustained 
ischemia, with p38 remaining activated but p38 deactivated. Furthermore, cells 
expressing a dominant negative p38, which prevented ischemia-induced p38 MAPK 
activation, were resistant to sustained ischaemic injury. Therefore, activation of p38 MAPK 
isoform is detrimental during ischemia. 
11. MAPK inactivation by phosphatases 
Dephosphorylation of either the threonine or tyrosine residue within the MAPK activation 
loop TxY motif alone can result in their enzymatic inactivation. In intact cells, 
dephosphorylation and inactivation of MAPK occur, within minutes to several hours 
depending on the cell type and activating stimulus. In endothelial cells, exposure to serum 
leads to ERK activation that is sustained at high levels for over 2 h. In contrast, different 
patterns can be observed in the a PC12 cell line where EGF-stimulated ERK activation is 
transient, with inactivation initiated within 5 min and nearly complete within 15-30 min, 
whereas this MAPK displays prolonged activation for several hours on stimulation with NGF 
[76]. It is believed that different patterns of ERK activation elicited by EGF and NGF underlie 
their differential effects to drive either cellular proliferation of differentiation, respectively [77]. 
Using PC12 cells as a model system to identify key phosphatases suppressing ERK activation, 
biochemical studies revealed that early rapid inactivation of these MAPKs reflects, in part, 
threonine dephosphorylation by the serine/threonine protein phosphatase PP2A [76].  
In addition to threonine dephosphorylation, these studies also indicated that tyrosine-
specific protein phosphatases (PTPs) also contribute to ERK inactivation [76]. Currently, 50 
or more PTPs have been characterized [78-80], and although the PC12 cell PTPs were not 
identified molecularly [76], recent studies in other cell types have identified a possible role 
for three related PTP gene family members [81-84]. Notwithstanding the importance of these 
early reports on PP2A and tyrosine-specific PTPs inactivating ERKs, little is known about 
their general importance in terminating MAPK signaling, of the molecular mechanisms that 
may control phosphatase catalytic activity, or of their specificity for inactivating different 
MAPK isoforms.  
In contrast to these protein phosphatase classes, there has been significant and rapid 
progress in our understanding of the role played by a subclass of PTP that possess activity 
for dephosphorylating both phosphotyrosine and phosphothreonine residues, known as the 
dual specificity phosphatases (DSPs).  
The first mammalian DSP was identified as the mouse immediate early gene 3CH134 or its 
human orthologue CL100, which is induced rapidly after exposure to growth factors, heat 
shock, or oxidative stress [85-87]. Recombinant CL100/3CH134 was shown to 
dephosphorylate threonine and tyrosine residues of ERK, which was paralleled by its 
inactivation. These studies showed that CL100/3CH134 was specific for dephosphorylation 
of ERK when compared to a number of other unrelated phosphoproteins [76]. A correlation 
between 3CH134 levels and ERK inactivation was also found in mammalian cells, leading to 
its renaming as MAPK phosphatase-1 (MKP-1) [88]. Despite this important early work, the 
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relevance of MKP-1 in ERK inactivation remains to be elucidated. Firstly, ERK activity is 
apparently normal after deletion of the MKP-1 gene in mice [89]. Secondly, it has also 
become evident that MKP-1 is at least as effective in inactivating JNK and p38 when 
compared to the ERKs [90-91].  Thirdly, newly identified members of the DSP gene family 
appear highly selective for ERK and may represent the true physiological regulators of this 
MAPK isoform.  Since the initial cloning of MKP-1, eight additional mammalian DSP gene 
family members have been identified and characterized, which include MKP-2, MKP-3, 
MKP-4, MKP-5, MKP-X, PAC1, M3/6 and B59. These DSPs all appear to be effective in 
mediating inactivation of MAPKs. 
The following model for MAPK inactivation by DSP is suggested (Figure 5). Stimulation by 
growth factors, cytokines, cellular stresses or some active oncogenes leads to rapid 
transcription of one or a subset of DSP genes. Increased DSP transcription may reflect 
activation of specific MAPK, although alternative pathways are not excluded. After 
translation of the DSP mRNA into protein, the catalytically inactive DSP translocates to a 
specific subcellular compartment within either the nucleus or the cytosol. Upon 
encountering its target MAPK, the DSP binds tightly through its amino terminus, which in 
turn triggers activation of the phosphatase catalytic domain. If the bound MAPK is already 
activated, then this will result in its rapid inactivation. Conversely, if the MAPK is not 
 
Figure 5. Cell exposure to growth factors, cytokines and cell stresses leads to induction of a subset of 
DSP genes. Increased expression is likely to reflect activation of transcription factors (black circles) via 
both MAPK-dependent and independent pathways. Newly synthesized DSPs translocate to specific 
subcellular compartments as dictated by anchorage and/or localization motifs not yet identified. 
Specific binding to target MAPKs through regions within the DSP amino terminus then triggers 
activation of the phosphatase catalytic domain. Bound MAPKs are in turn inactivated by 
dephosphorylation on threonine and tyrosine residues localized within the “activation loop” motif of 
TxY. Inactive MAPKs then dissociate, leaving the DSP free to bind and inactivate another MAPK 
molecule. In the absence of continued DSP gene transcription and protein synthesis, rapid degradation 
may limit their duration of activity in cells (Camps et al., 1999). 
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active, then its tight interaction with an active DSP is expected to block any possibility of 
kinase activation by a subsequent stimulus. MAPKs that fail to bind the DSP within its 
amino terminus remain active or susceptible to activation after extracellular stimulation. 
Depending on their cellular localization, these regulatory effects allow for selected inhibition 
of MAPK activities in specific subcellular compartments. Some DSPs have been shown to 
possess short half-lives [76], suggesting that in the absence of continued gene transcription 
and protein synthesis, their rapid turnover limits their duration of action in cells. Overall, 
tight control of DSP gene induction, combined with their differential binding and catalytic 
activation by a specific repertoire of MAPKs, provides a sophisticated mechanism for rapid 
targeted inactivation of selected MAPK activities.  
12. MAP kinase phosphatase-1 (MKP-1): A mediator of the beneficial 
effects of glucocorticoids during ischemia/reperfusion-induced stress in 
the heart 
It is noteworthy that many genes that are positively regulated at post-transcriptional level 
by p38-MAPK, are negatively regulated at the same level by glucocorticoids. Lasa and co-
workers investigated the effects of GCs on the p38-MAPK pathway and have shown that 
dexamethasone destabilized cyclooxygenase-2 (COX-2) mRNA by inhibiting the function, 
but not the expression of p38-MAPK [92]. The inhibition of p38-MAPK was then shown to 
be mediated by MKP-1. We and others have also demonstrated that dexamethasone induces 
the expression of MKP-1 which potently inactivated p38-MAPK [93-94].  
Wu and Bennet (2005) demonstrated that MKP-1 promotes cell survival in fibroblasts 
through the attenuation of stress responsive MAPK-mediated apoptosis [95]. Upregulation 
of MKP-1 has also been shown to be associated with cardioprotection by long-chain 
polyunsaturated fatty acids [93]. It has also been reported that transgenic mice 
overexpressing MKP-1 were protected, whereas knock-out mice show greater injury after 
ischemia/reperfusion [96]. The exact mechanism of the beneficial effects of glucocorticoids 
on the heart during ischemia/reperfusion-induced stress still remain to be established. In 
view of the significant contribution of apoptosis, necrosis and autophagy during 
ischemia/reperfusion-induced stress, it is expected that GC-induced cardioprotection to be 
associated with reduced apoptosis and necrosis. Indeed, Fan and co-workers have 
demonstrated that dexamethasone, administered intraperitoneally or added directly to the 
perfusate, significantly improved post-ischemic functional recovery and reduced infarct size 
compared to untreated controls [94]. These were associated with associated with 
upregulation of MKP-1 protein expression [94]. Furthermore, it was also shown by us that 
upregulation of MKP-1 during simulated ischemia/reperfusion is associated with an 
attenuation of apoptosis in neonatal cardiomyocytes [93].  
13. Conclusions  
It has been suggested that upregulation of MKP-1 during ischemia/reperfusion-induced 
stress attenuates myocardial injury [93,94]. MKP-1, found predominantly in the nucleus, is a 
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dual specific phosphatase which dephosphorylates phosphotyrosine and 
phosphothreonine-containing protein kinases such as the MAPKs. MAPKs are known to be 
involved in intracellular signalling pathways that regulate gene expression in response to a 
variety of extracellular signals. MAPKs are activated during ischemia/reperfusion-induced 
stress in the heart. It was also demonstrated that glucocorticoids act via MKP-1 induction 
and subsequent p38-MAPK inhibition to induce cardioprotection during 
ischemia/reperfusion-induced stress [94].  
MAPKs have been found to be involved in autophagic, apoptotic and necrotic cell death 
during stress responses of the heart [97-102]. Autophagy is foremost a survival mechanism 
which is activated in cells subjected to nutrient or growth factor deprivation. However, 
when the cellular stress continues, cell death may occur via autophagy, or becomes 
associated with features of apoptotic or necrotic cell death [103]. Apoptosis is essential for 
removal of specifically targeted cells, through the process of apoptotic body formation and 
phagocytosis [104]. Necrosis is a pathological cellular response requiring no ATP.  Necrotic 
cells are morphologically characterized by disrupted membranes, cytoplasm and 
mitochondrial swelling, disintegration of organelles and complete cell lysis [105]. Cell death 
following ischemia/reperfusion-induced stress is thought to manifest in morphological 
features indicative for all three, apoptotic, necrotic and autophagic cell death [106].  
MKP-1 has been shown to be involved in the regulation of apoptosis [107] and it was also 
very recently demonstrated that MKP-1 may lead to autophagy induction in cancer cells 
[108]. We have recently demonstrated that inhibition of MKP-1 and subsequent increased 
p38-MAPK phosphorylation during ischemia/reperfusion-induced stress is associated with 
attenuated autophagy and increased apoptosis and necrosis in the heart (unpublished data). 
We thus propose the following mechanism of GC-induced protection in the heart: During 
ischemia/reperfusion-induced stress in the heart, p38 MAPK is activated, GCs 
sustain/upregulate autophagy via an increase in MKP-1 and subsequent  dephosphorylation 
of  p38 MAPK which ultimately protects the heart from apoptosis and necrosis, driven by 
the effects of autophagy on the metabolic balance sheet of the heart.  
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